Live Breaking News & Updates on Asterias Biotherapeutics

SynAct Pharma Names James Knight as Chief Business Officer - Already published in Swedish today
SynAct Pharma AB (“SynAct”) today announced the appointment of James Knight as Chief Business Officer (CBO). He will head up business development and pipeline portfolio management and has more than 25 years of experience in the biopharmaceutical industry. Mr. Knight brings highly relevant experience and skills to the SynAct team as it advances its lead selective melanocortin asset AP1189 through Phase 2a clinical proof of concept trials.
Uppdaterad 2021-02-11
Publicerad 2021-02-11
James was formally the VP of Portfolio Strategy at Questcor Pharmaceuticals where he was responsible for leading the expansion of Acthar Gel from two promoted indications in two specialty audiences to nine promoted indications in five specialty areas including rheumatology. Questcor’s success in expanding Acthar use led to its acquisit ....

United States , University Of Massachusetts , Northeastern University , Asterias Biotherapeutics , Portfolio Strategy At Questcor Pharmaceuticals , Master Of Business Administration In High Technology , Head Of Corporate Development Biotime Inc , Portfolio Strategy , Questcor Pharmaceuticals , Acthar Gel , Senior Vice President , Corporate Development , California Based Biotime , Business Administration , High Technology , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் மாசசூசெட்ஸ் , வடகிழக்கு பல்கலைக்கழகம் , போர்ட்‌ஃபோலீயோ மூலோபாயம் , மூத்தவர் துணை ப்ரெஸிடெஂட் , பெருநிறுவன வளர்ச்சி , உயர் தொழில்நுட்பம் ,